Nucleic acids encoding GARP-TGF-beta 1 antibodies

US10875914B2 · kind B2 · utility

Assignees

• argenx BVBA · BE
• UNIVERSITÉ CATHOLIQUE DE LOUVAIN · BE

Inventors

• Sebastian Van Der Woning · Deinze, BE
• Filip Borgions · Herk-de-Stad, BE
• Torsten Dreier · Breda, NL
• Lore Mariën · Evergem, BE
• Gitte De Boeck · Malderen, BE
• Stéphanie Liénart · Wezembeek-Oppem, BE
• Sophie Lucas · Brussels, BE
• Pierre Coulie · Brussels, BE

Key dates

• Filing date: May 10, 2019
• Grant date: Dec 29, 2020
• Expiry date: May 10, 2039

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/94
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to antibodies and antigen binding fragments thereof, which bind to a complex of GARP and TGF-β1, particularly a complex of human GARP and human TGF-β1. These antibodies and antigen binding fragments exhibit a combination of advantageous properties including high affinity antigen binding and the ability to inhibit the release of active TGF-β from regulatory T cells. The antibodies and antigen binding fragments of the present invention are relatively resistant to deamidation, isomerization and oxidation, such that they display improved stability.